Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FORX-428 |
| Synonyms | |
| Therapy Description |
FORX-428 inhibits poly (ADP-ribose) glycohydrolase (PARG) and leads to increased sensitivity to DNA damage and replication stress, which may result in anti-tumor activity (Mol Cancer Ther (2025) 24 (10_Supplement): B022). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FORX-428 | FORX 428|FORX428 | FORX-428 inhibits poly (ADP-ribose) glycohydrolase (PARG) and leads to increased sensitivity to DNA damage and replication stress, which may result in anti-tumor activity (Mol Cancer Ther (2025) 24 (10_Supplement): B022). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07356453 | Phase I | FORX-428 | A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | Recruiting | USA | 0 |